All News

SERENA-6 shows early switch to oral SERD camizestrant plus CDK4/6 inhibitor improves PFS2, delays chemotherapy, and preserves quality of life.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

Apnimed has submitted an NDA for AD109 for obstructive sleep apnea following positive phase 3 results from the SynAIRgy and LunAIRo trials.

Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.

A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what it means for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how medication stigma and bias can impact patient recovery.

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, while others experience biologically driven GLP-1 resistance.

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss why patients struggle to access mental health and addiction treatment medications.

Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.

GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.

ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer versus chemo, with better tolerability and quality-of-life preservation.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types while emphasizing the need for prospective clinical research.

With no new kidney-protective therapies approved in T1D for over three decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss how stigma from health care providers or frontline staff impacts patient willingness to seek or continue treatment.

Pharmacy Times interviews Allison Burns, PharmD, RPh, the CEO of End Mass Overdose (EMO) Health to discuss common myths and misconceptions surrounding antidepressants, antipsychotics, and medications for addiction treatment in congregate care settings.

Phase 3 SARC041 shows abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.